Stock Ratings / Health Care / PEPG / financials

CNTN (37) PDSB (45) TRDA (21) VRXA (60) ⌘ Pro Terminal →

PepGen Inc. (PEPG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.36 -2.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.35

PepGen Inc. (PEPG) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $166.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PEPG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, PepGen Inc. (NASDAQ: PEPG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.36 (-2.08% 1D, market cap $166.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PEPG ranks #581 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PEPG compare to CNTN and PDSB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PEPG carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTN (Canton Strategic Holdings Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -4.1%, cap $163.3M) and PDSB (PDS Biotechnology Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M). Among the 5-stock peer group, PEPG leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PEPG?

▼

Per PEPG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835597), PepGen Inc. generated $0 in revenue, -$89.7M in net income, and -$81.9M in free cash flow against $173.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.35 (-0.56%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PEPG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY PEPG SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.49+8.4% Next Q

Q2 (-2Q)

Grade D$2.70-7.8% Next Q

Q3 (-1Q)

Grade D$2.49-5.2% Next Q

Current

Grade D-$2.36-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PEPG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PEPG currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.74) and Max Pain ($2.48) forces dealer call-delta covering toward $8.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PEPG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PEPG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PEPG Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.3%	-$89.7M	-$81.9M	-45%
FY 2024	$4.00B	52%	-2.4%	-$90.0M	-$82.9M	-45%
FY 2023	$4.00B	52%	-2.1%	-$78.6M	-$69.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PEPG)

✓Walkthrough of PEPG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PEPG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.11%▼ SUPPORT BREAKDOWN

2026-11-02O $2.47H $2.47L $2.31C $2.36VOL 216.3K

RES: $4.20SUP: $2.38SMA50: $2.74SMA200: $3.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PEPG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PEPG Butterfly Map → + Track PEPG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PEPG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PEPG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PEPG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PEPG)

Health Care Rank #581 of 1016 ⚔️ CNTN vs PEPG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PEPG vs. CNTN, PDSB, TRDA, VRXA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PepGen Inc. (PEPG) ranks #581 by composite RQD confidence (38/100, grade D-) and #599 by equity capitalization ($166.9M). Within this direct 5-issuer industry benchmark cohort, PEPG leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. VRXA currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with PEPG at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PEPG ACTIVE PepGen Inc.	D-	38/100	—	—	-35.0%	-2.08%	$166.9M	Benchmark Subject
CNTN Canton Strategic Holdings Inc.	D-	37/100	—	—	-4.1%	-4.88%	$163.3M	/cntn-vs-pepg →
PDSB PDS Biotechnology Corporation	D	45/100	—	—	-35.0%	-7.10%	$162.8M	/pdsb-vs-pepg →
TRDA Entrada Therapeutics Inc.	E	21/100	—	—	-35.0%	+3.07%	$171.3M	/trda-vs-pepg →
VRXA Veraxa Biotech AG	C-	60/100	—	—	—	+0.89%	$159.8M	/vrxa-vs-pepg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835597

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PepGen Inc. (PEPG) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$89.7M, operating cash flow of -$81.6M, and free cash flow of -$81.9M (+1.2% YoY). On the balance sheet, PEPG closed FY2025 with $173.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$89.7M	-$81.6M	-$81.9M	$173.9M	—
FY2024 (FY)	2024-12-31	$0	-$90.0M	-$82.4M	-$82.9M	$150.9M	—
FY2023 (FY)	2023-12-31	$0	-$78.6M	-$69.0M	-$69.0M	—	—

3. PEPG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PEPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PEPG compare to CNTN and PDSB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PEPG?

Where is PEPG trading relative to its 50-day, 200-day, and 52-week technical levels?

PEPG last traded at $2.36 (-2.08% on volume of 1,129,070 shares), positioning the stock -13.87% below its 50-day simple moving average ($2.74) and -21.85% below its 200-day simple moving average ($3.02). Across its 52-week range of $1.31 to $7.80, PEPG sits at the 16.2% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.07 to $2.65).

PEPG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is PepGen Inc. (PEPG)?

In FY 2025 (10-K), PEPG converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PEPG RQD Cockpit PEPG 12M Forecast PEPG Earnings & Move PEPG Dividends & DRIP PEPG Insiders & 13F PEPG Whale Options PEPG Profit Sankey PEPG News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PEPG — PepGen Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:42:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PEPG scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 7 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on invested capital or free cash flow. Whale 13F flow scores 6 of 20, reflecting weak institutional accumulation and options positioning signals. Insider conviction scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar, suggesting limited insider-driven confidence signals in the data. Macro regime fit scores 10 of 20 with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 10 of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the upside case depends on a balance sheet and cash-burn trajectory that the source data shows as currently unprofitable, so any valuation thesis rests heavily on future events rather than present cash generation. The rating reflects present-state vulnerability rather than a forecast of price direction.

Business

PepGen Inc. (PEPG) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each of the listed fiscal years, per the SEC financials. Market capitalization is recorded as $166.9M in the market data and approximately $0.2B in the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-93.6M	$-89.7M	N/A	$-81.9M	$60.5M	N/A
FY 2024	$0.0M	$-97.7M	$-90.0M	N/A	$-82.9M	$49.4M	N/A
FY 2023	$0.0M	$-84.8M	$-78.6M	N/A	$-69.0M	N/A	N/A

Per the SEC financials, operating losses and free cash outflows were reported in all three periods, with gross, operating, and net margins each recorded at 0% in the market data. ROIC is recorded at -35%, and the FCF yield at 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and the Debt/Equity ratio is 0.5. The reported cash balance rose from $49.4M in FY 2024 to $60.5M in FY 2025, while FCF remained negative in each period.

Recent Catalysts & News Wire Analysis

Per the recent news section, three items are tagged to PEPG. A Seeking Alpha item carries the headline "PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point," which identifies PGN-EDODM1 data as a potential inflection point. A TradingView item and a Globe and Mail item cover PEPG market action and institutional positioning, the latter alongside AbbVie (ABBV) in a healthcare analyst roundup. All three items are tagged YELLOW with a MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Open Questions

What is the specific development stage and clinical status of PGN-EDODM1, given the news item identifying its data as a major inflection point?
What are the forward P/E, EV/EBITDA, and EPS estimates, which are absent from the source data?
What is the debt composition behind the 0.5 Debt/Equity ratio, since debt is recorded as N/A in every reported period?
What is the current cash runway relative to the reported FY 2025 free cash outflow of $-81.9M?
What institutional or insider holdings exist, given that holders and analyst data are both unavailable?

PEPG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PepGen Inc. (PEPG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PEPG Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 6h ago

PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point

Seeking Alpha report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 9h ago

PepGen Inc. Estimates – NASDAQ:PEPG

TradingView report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 12h ago

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG)

The Globe and Mail report covering PepGen Inc. (PEPG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 88d ago

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

BOSTON, August 06, 2026--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 88d ago

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

BOSTON, August 06, 2026--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 168d ago

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

PepGen Inc. (NASDAQ:PEPG) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, PepGen reported Q1 2026 financial results, recording a net loss of $17.8 million, or $0.26 per share, compared to a net los

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 215d ago

PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway

PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what managem

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 166d ago

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PEPG Bull vs. Bear Conversation Board — What's Your Call at $2.36?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PEPG 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.12 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PEPG (D- • RQD 38/100) a Buy at $2.41?

Welcome to the PEPG (PepGen Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.86 (-22.8%)

Spot @ $2.41

Pump the brakes on PEPG — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PEPG, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless PepGen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.92 (+21.2%)

Spot @ $2.41

PEPG cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PEPG, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.41 (52-wk range $2.17 - $2.70), any beat on forward guidance forces shorts and underweight funds to chase.